Trial Profile
The DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) trial.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Aug 2023
Price :
$35
*
At a glance
- Drugs Ramipril (Primary) ; Rosiglitazone (Primary)
- Indications Atherosclerosis; Cardiovascular disorders; Death; Diabetes mellitus; Glucose intolerance; Heart failure; Kidney disorders; Type 2 diabetes mellitus
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms DREAM
- 22 Apr 2011 Results of an analysis following drug withdrawal published in the Diabetes Care.
- 20 Sep 2006 Status change
- 14 Sep 2006 Primary endpoint 'Death-rate' has not been met for ramipril according the results presented at the Annual Meeting of the European Association for the Study of Diabetes.